CDXC
ChromaDex Corporation
Set alert
52-week range unavailable
- YTD
- +48.21%
- 1 year
- +163.21%
- Open
- 7.91
- Prev close
- 7.87
- Mkt cap
- 404.83M
- Vol
- 541.67K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.75
- High
- 7.92
- Forward P/E
- 44.17
- Beta
- 1.88
- Short ratio
- 0.72
- Inst. own
- 23.92%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.81
- 200-d avg
- 3.86
- 1y target
- 7.96
Key statistics
- Market cap
- 404.83M
- Enterprise value
- 390.91M
- Trailing P/E
- 265.00
- Forward P/E
- 44.17
- PEG ratio
- 0.00
- Price / sales
- 4.42
- Price / book
- 11.75
- EPS (TTM)
- 0.02
- Beta
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 1.62%
- Revenue (TTM)
- 91.67M
- Revenue growth
- 31.20%
- Free cash flow
- 4.38M
- Total cash
- 32.25M
- Total debt
- 2.90M
- Return on equity
- 4.81%
- Shares outstanding
- 76.38M
- Short % of float
- 4.04%
- 50-day average
- 5.81
- 200-day average
- 3.86
Analyst view
Consensus: none
- Target (low)
- 5.00
- Target (mean)
- 7.96
- Target (high)
- 12.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.018.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | 0.01 | 0.02 | +0.01 | +100.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.03 | 0.00 | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.03 | -0.01 | +0.02 | +66.67% |
| Mar 6, 2024 | Dec 1, 2023 | -0.03 | 0.00 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -0.03 | -0.01 | +0.02 | +66.67% |
| Aug 9, 2023 | Jun 1, 2023 | -0.04 | -0.03 | +0.01 | +25.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | Roth MKM | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2024 | Roth MKM | main | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Country
- United States
- Website
- chromadex.com
News
- Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
- Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
- ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
- ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
- ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- Earnings Scheduled For March 4, 2025
Your note
Sign in to keep a note on CDXC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAMPION RIVER VENTURES, LTD. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 5, 2023 | 0 |
| CHAU HOI SHUEN SOLINA HOLLY | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 19, 2024 | 0 |
| FRIED ROBERT N | Chief Executive Officer | Purchase | May 30, 2023 | 0 |
| GERBER BRIANNA | Chief Financial Officer | Purchase | Nov 30, 2023 | 28,674 |
| JAKSCH FRANK LOUIS JR | Director | Sale | Dec 12, 2024 | 2,319,230 |
| LI KA SHING | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 19, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.49% | 3,430,356 | 18.18M | Sep 29, 2024 |
| Blackrock Inc. | 4.45% | 3,395,358 | 18.00M | Sep 29, 2024 |
| Tieton Capital Management, LLC | 3.87% | 2,956,120 | 15.67M | Sep 29, 2024 |
| ICONIQ Capital, LLC | 1.70% | 1,296,354 | 6.87M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.51% | 1,149,592 | 6.09M | Sep 29, 2024 |
| State Street Corporation | 0.81% | 618,028 | 3.28M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.88% | 2,196,484 | 11.64M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.58% | 1,210,404 | 6.42M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.02% | 776,070 | 4.11M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.66% | 501,704 | 2.66M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.55% | 421,392 | 2.23M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.39% | 299,190 | 1.59M | Oct 30, 2024 |